Bruno Emond

17PUBLICATIONS
22CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsPredictive and prognostic markersHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 29, 2026
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.

|Jun 02, 2026
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma.

|Nov 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.

Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald

|Jul 12, 2025
Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.

Matthew J Pianko, Niodita Gupta-Werner, Bruno Emond

|Apr 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi

|Feb 23, 2024
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.

Christine M Bestvina, Dexter Waters, Laura Morrison

Pageof 3

Frequent Collaborators

2 joint publications

Julie Vanderpoel

2 joint publications

Andrea L Stevens

2 joint publications

Carmine Rossi

2 joint publications

Zaina P Qureshi